Capstan Therapeutics, Inc., a biotechnology company dedicated to advancing in vivo reprogramming of cells through targeted lipid nanoparticles, today announced that Capstan President and Chief Executive Officer, Laura Shawver, Ph.D., will participate in the upcoming Cowen 43rd Annual Health Care Conference, being held between March 6-8, 2023 at the Boston Marriott Copley Place in Boston, MA.
Capstan will be hosting one-on-one meetings with investors on Monday, March 6.
About Capstan (www.capstantx.com)
Capstan Therapeutics is a biotechnology company dedicated to advancing in vivo cell reprogramming. The core platform technology comprises proprietary targeted lipid nanoparticles (tLNPs) that are composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. The platform technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including oncology, autoimmune disorders, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005664/en/
Contacts
Investors:
Miguel Arcinas
Vice President of Corporate Development
Capstan Therapeutics
marcinas@capstantx.com
Media:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
